8-K: Amwell Reports Improved Outlook for 2024 Adjusted EBITDA in Second Quarter Results

Amwell announced its second quarter 2024 financial results, highlighting progress in cost alignment and an improved adjusted EBITDA outlook for the year.

Summary

• Amwell released its financial results for the second quarter of 2024, showing a total revenue of $62.8 million.
• Subscription revenue reached $27.5 million, while Amwell Medical Group (AMG) visit revenue was $28.7 million.
• The company reported a gross margin of 37%.
• Net loss for the quarter was ($49.9) million, an improvement from ($73.4) million in the first quarter of 2024.
• Adjusted EBITDA was ($35.0) million, also an improvement from ($45.7) million in the previous quarter.
• Total visits were 1.5 million, with approximately 70% of those visits occurring on the Converge platform.
• Amwell has improved its 2024 adjusted EBITDA guidance by $10 million, now forecasting a range of ($150) million to ($145) million.
• The company reiterated its 2024 revenue guidance of $259 to $269 million and AMG visit guidance of 1.6 to 1.7 million.
• Amwell is targeting adjusted EBITDA breakeven in 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to improved financial metrics and an increased EBITDA outlook, but the company is still operating at a loss and faces significant risks.

Positives

• The company's net loss improved significantly from the first quarter of 2024, decreasing from ($73.4) million to ($49.9) million.
• Adjusted EBITDA also showed improvement, moving from ($45.7) million in Q1 to ($35.0) million in Q2.
• Amwell increased its 2024 adjusted EBITDA guidance by $10 million.
• The company is making progress on its cost alignment efforts.
• The company is continuing the deployment of its solution for the U.S. Military Health System.

Negatives

• The company still reported a net loss of ($49.9) million for the quarter.
• Adjusted EBITDA remains negative at ($35.0) million.
• The company is still not profitable and is targeting adjusted EBITDA breakeven in 2026.

Risks

• The company faces risks related to transitioning clients to the Converge platform without significant attrition.
• There are risks associated with renewing and upselling the client base.
• The company's relationship with the Defense Health Agency (DHA) is subject to renewal and comparable financial terms beyond July 2025.
• The telehealth market is experiencing weak growth and increased volatility.
• The company must adapt to rapid technological changes.
• Increased competition from existing and potential new participants in the healthcare industry is a risk.
• Changes in healthcare laws, regulations, or trends could impact the company.
• The company must comply with federal and state privacy regulations.
• A cybersecurity breach could result in significant liability.

Future Outlook

Amwell anticipates a step function in growth in 2025, leading to adjusted EBITDA breakeven in 2026. The company has improved its 2024 adjusted EBITDA guidance and reiterated its revenue and visit guidance for the year.

Management Comments

• Ido Schoenberg, M.D., chairman and CEO of Amwell, stated that the company drove progress on all fronts in Q2.
• Dr. Schoenberg noted that ongoing cost alignment efforts resulted in an improved outlook for 2024 adjusted EBITDA.
• Dr. Schoenberg emphasized the company's focus on key strategies that support their guidance, which calls for a step function in growth in 2025 leading to adjusted EBITDA breakeven in 2026.

Industry Context

This announcement comes as the telehealth industry faces increased competition and market volatility. Amwell's focus on cost alignment and platform growth is in line with the need for sustainable business models in the sector. The company's emphasis on its Converge platform and its relationship with the U.S. Military Health System are key differentiators in the market.

Comparison to Industry Standards

• Teladoc, a major competitor in the telehealth space, reported a net loss of $69.2 million in their most recent quarter, which is worse than Amwell's $49.9 million loss, but Teladoc's revenue was significantly higher at $652.4 million.
• Similar to Amwell, many telehealth companies are focusing on cost reduction and platform integration to improve profitability.
• The industry is seeing a trend towards hybrid care models, which Amwell is positioning itself to capitalize on with its Converge platform.
• Amwell's adjusted EBITDA loss of $35 million is still significant, but the improvement from the previous quarter indicates progress in cost management, which is a key focus for investors in the current market.

Stakeholder Impact

• Shareholders may view the improved financial results and outlook positively.
• Employees may be impacted by ongoing cost alignment efforts.
• Customers may benefit from the continued deployment of the Converge platform.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• Amwell will continue to focus on deploying its solution for the U.S. Military Health System.
• The company will continue its cost alignment efforts.
• Amwell will focus on transitioning clients to the Converge platform.
• The company will work towards achieving adjusted EBITDA breakeven in 2026.

Key Dates

Keywords

telehealth, digital health, hybrid care, EBITDA, revenue, healthcare, Amwell, Converge, financial results, medical group